<DOC>
	<DOC>NCT00380302</DOC>
	<brief_summary>Primary: This study is being conducted to evaluate if AVE1625 is safe and tolerated in patients with Alzheimer's disease that is not too severe. There is also evaluation of whether patients who take the study medication improve compared to patients who take a placebo (sugar pill). Secondary:The study will also evaluate the blood levels of the study medication, AVE1625 in patients who join the study.</brief_summary>
	<brief_title>Activity of AVE1625 in Mild to Moderate Alzheimer's Patients.</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>The diagnosis of Alzheimer's disease Recent brain image(Computerized Axial Tomographic Scan CAT scan or Magnetic Resonance Imaging MRI) Mild to moderate range of disease; not too severe Severe or unstable medical diseases Neurological disorder other than Alzheimer's disease Depression that is not well controlled Treatment with memantine Inpatient in a total care facility (e.g.: Nursing home) Lack of reliable caregiver</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2008</verification_date>
	<keyword>Alzheimer's disease</keyword>
	<keyword>symptomatic</keyword>
	<keyword>cognition</keyword>
</DOC>